2 results match your criteria: "Forest Research Institute (now Actavis)[Affiliation]"
Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder.
J Am Acad Child Adolesc Psychiatry
December 2015
Forest Research Institute (now Actavis), an Allergan affiliate; Janssen Pharmaceuticals, Titusville, NJ.
Objective: To evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes.
Method: In this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg b.
Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.
J Affect Disord
January 2016
Forest Research Institute (now Actavis), Jersey City, NJ, USA. Electronic address:
Background: Asenapine is an atypical antipsychotic for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. The recommended asenapine starting dose is 10mg bid with the option to reduce the dose to 5mg bid if needed due to adverse effects/tolerability.
Methods: Phase IIIb, international, double-blind, fixed-dose, parallel-group, 3-week placebo-controlled trial of asenapine 5 and 10mg bid in adults with an acute bipolar I disorder manic or mixed episode.